Reforgene recognized as a technology-based SME
After selection and public announcement, Reforgene officially became a technology-based small and medium-sized enterprise of Guangdong Province. Technology-based SMEs are evaluated in accordance with the Measures for the Evaluation of Technology-based Small and Medium-sized Enterprises (Guokefazheng [2017] No. 115) and the Guidelines for the Evaluation of Technology-based Small and Medium-sized Enterprises (Trial) (Guokehuozi [2017] No. 44).
Technology-based SMEs are enterprises whose main body consists of scientific and technical personnel, led and founded by such personnel, mainly engaged in the scientific research, development, production and sales of high-tech products, with the commercialization of scientific and technological achievements and technology development, technical services, technical consulting and high-tech products as their main content. Guided by the market, such enterprises obtain independent intellectual property rights and transform them into high-tech products or services, thereby achieving sustainable development.
Reforgene is a high-tech enterprise dedicated to developing gene medicines with curative value. Its R&D team comes from well-known academic research institutions such as Sun Yat-sen University, the University of Texas MD Anderson Cancer Center and New York University. Centered on technologies such as gene editing and genomics, the company develops innovative medicines for human diseases including genetic diseases, major chronic diseases and cancer.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.